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Background: The objective of this study was to explore whether individual variations in the concentration of growth factors (GFs) 
influence the biologic effects of platelet-rich plasma (PRP) on human mesenchymal stem cells (HMSCs).
Methods: The concentrations of 7 representative GFs in activated PRP (aPRP) were measured using ELISA. The effects of PRP on the 
proliferation and alkaline phosphatase (ALP) activity of HMSCs were examined using several concentrations of aPRP from 3 donors; 
the relationships between the GF levels and these biologic effects were then evaluated using 10% aPRP from 5 subgroups derived 
from 39 total donors. HMSCs were cultured in DMEM with the addition of aPRP for 4 or 12 days; then, DNA content and ALP activity 
were measured. 
Results: The quantity of DNA increased significantly at a 10% concentration of aPRP, but the ALP activity was suppressed at this 
concentration of aPRP. The GF concentrations varied among donors, and 5 subgroups of characteristic GF release patterns were 
identified via cluster analysis. DNA levels differed significantly between groups and tended to be higher in groups with higher con-
centrations of transforming growth factor-beta1 (TGF-β1) and platelet-derived growth factors (PDGFs). DNA quantity was positive-
ly correlated with TGF-β1 concentration, and was negatively correlated with donor age. ALP activity was negatively correlated with 
PDGF-BB concentration. 
Conclusions: The varying GF concentrations may result in different biologic effects; thus, individual differences in GF levels should 
be considered for reliable interpretation of the biologic functions and standardized application of PRP.
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INTRODUCTION
Platelets, the fundamental component of primary hemo-
stasis, are also known to be reservoirs for many growth fac-
tors (GFs), which they store in their α-granules. Platelet ag-
gregation and activation, after vascular damage, result in 
the release of several GFs that may affect the chemotaxis, 
proliferation, and differentiation of mesenchymal stem cells 
(MSCs) or other committed cells during the process of tis-
sue repair and healing [1]. The GFs released from platelets 
include platelet-derived growth factors (PDGFs), trans-
forming growth factor-beta (TGF-β), vascular endothelial 
growth factor (VEGF), epidermal growth factor (EGF), fi-
broblast growth factor (FGF) and insulin-like growth fac-
tors (IGFs) [2, 3]. 
To explore the possibility that platelet-rich plasma (PRP) 
could provide an autologous source of these essential GFs 
that benefit bone and soft tissue healing [4], many clinical 
and experimental studies dealing with the effects of PRP 
have been conducted [5-7]. However, the benefit of PRP on 
bone formation is a controversial subject. While a report 
suggested a stimulatory effect with the addition of PRP [5], 
others have observed no improvement [6] or have detected Cho HS, et al.  •  Individual Variation of the PRP Effect
www.kjlm.org     213 DOI 10.3343/kjlm.2011.31.3.212
KJLM
even inhibitory effects [7]. Although the lack of standard-
ization in application across these studies, including differ-
ences in the preparation method or dosage of PRP, bioma-
terials, species, implantation sites, and cell types, may have 
contributed to the inconsistent results [8], we hypothesized 
that the differences in GF composition among PRPs could 
lead to this discrepancy. GF quantities vary significantly be-
tween individuals [9]. The potential efficacy of PRP depen-
ds on the levels of GFs released from platelets; however, no 
study has yet addressed the relationship between the bio-
logic effects and GF concentrations in PRP. In this study, we 
attempted to explore the variations in GF release patterns in 
PRP in order to determine whether differences in GF con-
centrations influence biologic effects such as proliferation 
and alkaline phosphatase (ALP) activity of human MSCs 
(HMSCs) and to identify the factors associated with each of 
these biologic effects. 
MATERIALS AND METHODS
This study was reviewed and approved by the Institutional 
Review Board of Yeungnam University College of Medicine. 
Prior to drawing blood or bone marrow, informed consent 
was obtained from each donor.
1. Preparation of PRP and measurement of GF concentrations
First, PRPs were obtained from 3 healthy male volunteers 
(27 yr, 39 yr, and 43 yr old) to explore the effects of PRP con-
centration on the proliferation and ALP activity of HMSCs. 
Then, we obtained donated PRPs from 39 other healthy vol-
unteers to assess the relationship between the effects and GF 
concentrations. The mean donor age was 42 yr (range, 24-
68 yr), distributed at 6-8 individuals per decade. We limited 
our subjects to those who had not taken anti-platelet medi-
cations within 1 week of donation; further, to minimize the 
possible influences of hormonal variation on the prolifera-
tion of HMSCs, we included only male donors. 
PRPs were prepared via double centrifugation of blood. 
In brief, 9 mL of venous blood was drawn into a polypropyl-
ene tube containing 1 mL of anticoagulant, acid citrate dex-
trose (ACD). The blood was centrifuged at 1,500 rpm for 10 
min at 25˚C to separate the platelet-containing plasma from 
the red cells. The platelet-containing plasma was then cen-
trifuged at 3,000 rpm for an additional 10 min at 25˚C, and 
platelet-poor plasma (PPP) was separated out. Platelet pel-
lets were resuspended in 1 mL of plasma and were pooled 
for PRP. To activate the platelets, 1 part bovine thrombin 
stock solution (1,000 U/mL; Sigma, St. Louis, MO, USA) 
was added to 9 parts PRP or PPP to yield a final thrombin 
concentration of 100 U/mL. Each sample was incubated for 
1 hr at 37˚C [10]. The resulting supernatants from the clot 
preparation were referred to as activated PRP (aPRP) and 
activated PPP (aPPP). Both aPRPs and aPPPs were stored at 
-80˚C until use. The concentrations of PDGF-AA, PDGF-
AB, PDGF-BB, TGF-β1, FGF-basic (FGF-b), IGF-1, and 
VEGF were measured with commercially available Quanti-
kine colorimetric sandwich ELISA kits (R&D Systems, Min-
neapolis, MN, USA) according to the manufacturer’s in-
structions.
2. Cell isolation
HMSCs were cultured using established protocols [11]. 
Bone marrow aspirate was obtained with consent from a 
50-yr-old female patient who had undergone an autologous 
bone graft for the treatment of degenerative spondylolithe-
sis. Mononuclear cells were isolated using a density gradient 
and were cultured in DMEM (Sigma, St Louis, MO, USA) 
with 10% fetal bovine serum (FBS), penicillin, and strepto-
mycin (Gibco-BRL, Rockville, MD, USA). The cells were 
incubated in a humidified atmosphere of 5% CO2 at 37˚C. 
Non-adherent cells were discarded after 24 hr, and the me-
dium was exchanged every 3 days. First passage (P1) cells 
were utilized in the study. 
3. The effects of aPRP and aPPP on the DNA content and 
  ALP activity of HMSCs 
The cells were seeded at a density of 1.5×10
4 cells/well in 
12-well plates (35 mm diameter) and were allowed to attach 
for 24 hr. After this adhesion period, the medium was re-
moved and was replaced with DMEM with 10% FBS (as 
control) or variable volume concentrations of aPRP and 
aPPP (1%, 3%, 10%, and 30%) from each of the 3 donors. 
Each experiment was conducted in triplicate. Media was 
exchanged every 4 days. The level of DNA and ALP activity 
were measured in quadruplicate on the fourth and twelfth 
days. The DNA level was measured via Hoechst DNA stain, 
and ALP activity was determined by quantifying the p-ni-
trophenol released from p-nitrophenol phosphate [12].
4. Relationships between GF concentrations, DNA content, 
  and ALP activity of HMSCs
In order to evaluate the effects of aPRP GF concentrations 
on the proliferation or ALP activity of HMSCs, the HMSCs 
were cultured under the same conditions as described above, 
in DMEM with 10% aPRPs from each of the 39 donors. Af-
ter culturing for 12 days, the DNA contents and ALP activity 
were measured.214     www.kjlm.org
Cho HS, et al.  •  Individual Variation of the PRP Effect
DOI 10.3343/kjlm.2011.31.3.212
KJLM
5. Statistical analysis
Statistical analysis was conducted using the Predict Ana-
lytics Software program (PASW) version 18.0 (SPSS Inc., 
Chicago, IL, USA). The Shapiro-Wilk test was used to ana-
lyze the normal distribution of the data. The effects of aPRP 
and aPPP concentrations on the DNA content and ALP ac-
tivity of HMSCs were evaluated via ANOVA, or the Krus-
kal-Wallis (K-W) test with Bonferroni correction. The dif-
ferences in GF concentrations between aPRPs and aPPPs 
were examined using the paired t-test. Pearson’s correlation 
analysis was used to identify correlations between GF levels 
and age, platelet count, or mean platelet volume. The aPRP 
release pattern of GFs was grouped via cluster analysis using 
the K-means method. The relationships between GF con-
centrations and the biologic effects between these groups 
was analyzed using ANOVA or K-W test with Bonferroni 
correction. Stepwise multiple linear regression analysis was 
employed to show which GFs were associated with DNA 
content or ALP activity. Significant differences were estab-
lished at P<0.05; the Bonferroni corrected P value thresh-
old (0.05/number of comparison) was employed for post-
hoc analysis of the K-W test. 
RESULTS
1. Effects of PRP and PPP on the DNA content and ALP 
  activity of HMSCs 
On the fourth day after cultivation, DNA contents were 
unaffected by the addition of aPRP (P=0.043 by K-W test, 
but multiple comparisons with Bonferroni correction did 
not reveal significant differences). The addition of aPPP did 
not affect DNA content at any concentration (P=0.408 by 
ANOVA). However, by the twelfth day, DNA levels differed 
significantly according to the aPRP and aPPP concentra-
tions. Both aPRP and aPPP, at a concentration of 10% re-
sulted in increased DNA levels. However, DNA levels were 
reduced by aPPP at a concentration of 30% (P<0.001 by 
ANOVA, post-hoc analysis using Scheffe method; Fig. 1A). 
The stimulatory effects of aPRP were significantly greater 
than those of aPPP (P=0.006 by paired t-test). The ALP ac-
tivity of cultured HMSCs was reduced with the addition of 
aPRP (P<0.001 by ANOVA), but the addition of aPPP did 
not affect the cellular ALP activity (P=0.564 for the fourth 
day; P=0.094 for the twelfth day; both by ANOVA; Fig. 1B). 
2. Characteristics and concentrations of GFs in aPRP and aPPP
Plasma samples from 39 individuals were evaluated in this 
portion of the study. Platelet counts in native whole blood 
(WB) varied by individual, ranging from 117×10
9/L to 
337×10
9/L (mean, 192±50×10
9/L). The platelet count was 
significantly higher in the PRP samples than in native blood 
(P<0.001 by paired t-test), with an average 6-fold increase; 
we noted a relatively high degree of variability among indi-
viduals (mean, 1,166±402×10
9/L; range, from 400×10
9/L 
to 2,505×10
9/L; Table 1). The Pearson’s correlation between 
the WB and PRP platelet count was 0.673 (P<0.001). The 
platelet counts were not correlated with donor age (P=0.222 
for WB platelet count; P=0.685 for PRP platelet count). 
The GF concentrations, with the exception of IGF-1, were 
significantly higher in aPRPs than in aPPPs (Fig. 2). The 
concentration of GFs also displayed considerable variation 
across donors, and the concentrations of TGF-β1, PDGFs, 
Fig. 1. The DNA concentration (A) and ALP activity (B) of human mesenchymal stem cells after the addition of 1%, 3%, 10%, and 30% activated PRP or activated 
PPP. Each value is the mean of 3 donors, with the error bar showing one standard deviation (*P<0.05; **P<0.01 compared with control).
Abbreviations: ALP, alkaline phosphatase; PRP, platelet-rich plasma; PPP, platelet-poor plasma.
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Table 1. Donor characteristics (N=39)
PLT in WB
(×10
9/L) 
PLT in PRP
(×10
9/L)
PLT in PPP
(×10
9/L)
Recovery rate 
of PLT (%) Age (yr)
192±50 1,166±402 27±17 61±17 42.4±13.5
(117-337) (400-2,505) (2-76) (27-97) (24-68)
Values are mean±standard deviation (minimum-maximum).
Abbreviations: PLT, platelet count; WB, whole blood.Cho HS, et al.  •  Individual Variation of the PRP Effect
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and FGF-b were correlated with the platelet count in both 
WB and PRP. The concentrations of PDGF-BB and IGF-1 
displayed weak negative correlation with age (Table 2). 
3. Cluster analysis of 7 GFs and between-group differences
  in DNA levels or ALP activity in HMSCs
We performed a cluster analysis using the K-means me-
thod to identify the variations in GF release patterns and 
their influences on the biologic effects. Five characteristic re-
lease patterns of aPRP GFs were identified and significant 
differences in PDGF-AA, PDGF-AB, PDGF-BB, TGF-β1 
and IGF-1 were noted between the groups. Groups 1 and 3 
showed higher concentrations of TGF-β1 and PDGFs, wher-
eas groups 2 and 4 exhibited lower concentrations of TGF-β1 
and PDGFs. Groups 1 and 2 showed higher concentrations 
of IGF-1, whereas groups 3 and 4 showed lower concentra-
tions of IGF-1. Group 5 exhibited substantially lower concen-
trations of TGF-β1, PDGFs, and FGF-b; however, the group 
was excluded from ANOVA because its sample size was only 
1. The DNA levels differed significantly between groups 
(P=0.007 by ANOVA) and were higher in groups 1 and 3 
than in group 4. The differences in ALP activity between 
cluster groups were not significant (P=0.289 by K-W test; 
Table 3). 
Table 2. Pearson’s correlation coefficients for age, platelet count, and growth 
factor levels. 
Age PLT in WB  PLT in PRP  Recovery rate MPV
TGF-β1 -0.307 0.444
† 0.604
† 0.391* -0.162
PDGF-AA -0.046 0.524
† 0.707
† 0.383* -0.205
PDGF-AB -0.122 0.516
† 0.647
† 0.318* -0.207
PDGF-BB -0.322* 0.476
† 0.644
† 0.371* -0.278
FGF-b 0.315 0.416
† 0.419
† 0.056 -0.162
VEGF 0.158 0.110 0.283 0.312 -0.172
IGF-1 -0.393* 0.227 0.110 -0.035 0.156
*p<0.05; 
†p<0.01.
Abbreviations: TGF-β1, transforming growth factor-β1; PDGF, platelet-derived growth 
factor; FGF-b, fibroblast growth factor-basic; VEGF, vascular endothelial growth fac-
tor; IGF-1, insulin-like growth factor-1; PLT, platelet count; WB, whole blood; MPV, 
mean platelet volume.
Fig. 2. Quantification of growth factors in activated PRP and activated PPP 
(P<0.05 between PRP and PPP, except for IGF-1).
Abbreviations: TGF-β1, transforming growth factor-β1; PDGF, platelet-de-
rived growth factor; IGF-1, insulin-like growth factor-1; FGF-b, fibroblast 
growth factor-basic; VEGF, vascular endothelial growth factor.
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Table 3. Cluster characteristics of growth factors and biologic effects  
Cluster I (N=6) Cluster II (N=11) Cluster III (N=8) Cluster IV (N=13) Cluster V (N=1) P value Post-hoc test
‡
TGF-β1 110,683±8,200 83,482±6,864 107,925±7,567 78,023±10,466 43,000 <0.001* I, III>II, IV
PDGF-AA 13,950±2,622 12,082±1,386 14,762±2,205 11,531±1,121 5,500 0.001
† III>II, IV
PDGF-AB 73,150±6,155 51,182±12,647 78,075±8,044 45,623±6,352 15,300 <0.001* I, III>II, IV
PDGF-BB 19,283±3,264 14,218±4,373 20,300±3,437 11,846±2,377 5,300 <0.001
† I, III>II, IV
FGF-b 10.5±2.7 9.5±2.8 12.0±3.4 9.4±3.2 5.0 0.256
†
IGF-1 114,113±15,823 108,636±13,726 67,929±13,838 68,332±11,580 82,710 <0.001
† I, II>III, IV
VEGF 1,070±565 1,159±772 1,464±862 650±591 259 0.079*
DNA  3.95±0.41 3.58±0.32 3.95±0.40 3.41±0.40 3.71 0.007
† I, III>IV
ALP 7.66±5.12 6.52±2.02 5.01±1.25 6.45±1.69 11.95 0.289*
Values are mean±standard deviation.
Units: growth factors, pg/mL; DNA, μg/well; ALP, nM pNP/min/μgDNA. 
P values were determined by *Kruskal-Wallis test, or by 
†one-way ANOVA, 
‡Post-hoc tests were conducted using the Bonferroni correction for the Kruskal-Wallis test or the Scheffe 
method for ANOVA. 
Abbreviations: TGF-β1, transforming growth factor-β1; PDGF, platelet-derived growth factor; FGF-b, fibroblast growth factor-basic; IGF-1, insulin-like growth factor-1; VEGF, vascu-
lar endothelial growth factor; ALP, alkaline phosphatase. 216     www.kjlm.org
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4. Relationship between DNA content or ALP activity and 
  aPRP GF concentrations
The amount of DNA obtained from HMSCs that were 
cultured for 12 days with 10% aPRPs varied by donor, rang-
ing from 2.59 to 4.59 μg/well (mean, 3.66±0.43 μg/well). 
The ALP activity per cell also showed considerable individ-
ual variations, ranging from 2.83 to 17.96 nM pNP/min/μg 
DNA (mean, 6.50±2.68 nM pNP/min/μg DNA). 
Stepwise multiple regression analysis was employed to 
identify the independent variables that affected DNA levels 
and ALP activity. The variables included were donor age, 
the WB and PRP platelet count, the platelet recovery rate, 
and aPRP concentrations of the 7 GFs. The amount of DNA 
was correlated positively with the TGF-β1 concentration 
(Beta=0.500, P<0.001) and negatively with donor age 
(Beta=-0.324, P=0.017; Table 4). The ALP activity (ALP/
DNA) was correlated negatively with the concentration of 
PDGF-BB (Beta=-0.418, P=0.008; Table 4).
DISCUSSION
Despite 2 decades of clinical study of PRP, little basic data 
is available regarding the effects of variations in GF levels on 
biologic function. Because PRP displays the unique charac-
teristics of a mixture of multiple GFs in various concentra-
tions, and because the regenerative potency of PRP proba-
bly depends on its GF levels, knowledge of the relationships 
between GF levels and biologic effects is required to ensure 
the reliable and reproducible use of PRP [8]. Therefore, in 
this study, we attempted to explore the relationship between 
GF levels and biologic effects. 
Obtaining a sufficiently large volume of blood from the 
single donor in order to analyze the various effects was dif-
ficult; thus, we employed DNA analysis for proliferation 
markers and ALP activity for osteogenic markers of HM-
SCs. First, we cultured HMSCs at several aPRP concentra-
tions (1%, 3%, 10%, and 30%) from 3 donors to evaluate its 
effects on proliferation and ALP activity, as well as to deter-
mine the optimal concentration in our experimental set-
ting. Simultaneously, HMSCs were cultured with the same 
concentrations of aPPPs in an effort to demonstrate that the 
effects were attributable to the presence of platelets. Then, 
HMSCs were cultured with 10% aPRPs from another 39 
donors to assess the relationship between the biologic ef-
fects and GF concentrations. 
Our findings indicated that aPRP induced HMSC prolif-
eration in a dose-dependent manner. The addition of 10% 
aPRP to the culture medium induced marked cell prolifera-
tion in vitro; this result was consistent with the findings of 
previous studies [13, 14]. Because higher concentration 
(30%) of aPRP did not promote proliferation, as compared 
to controls, 10% aPRP may be optimal for the experimental 
ex vivo expansion of HMSCs. Some studies also showed that 
a high concentration of PRP did not promote or that it even 
suppressed cell proliferation; optimal concentration varied 
with the cell type or preparation method [15-17]. Few stud-
ies have suggested the presence of negative regulators in PRP, 
such as thrombospondin [17], but the reason for the antip-
roliferative effect of high-concentration-PRP is not clear. Al-
though aPPP could promote cell proliferation when it is acti-
vated, the proliferative effect of aPPP was significantly lower 
than that of aPRP in this and some other studies. Non-acti-
vated PPP cannot induce cell proliferation; therefore, the 
proliferative effect of aPPP also might be attributed to plate-
let-derived factors [16, 18]. However, why higher concentra-
tions of aPPP suppress HMSCs is still unclear. 
In the present study, aPRP suppressed the ALP activity of 
MSCs. Some studies have reported similar results in that 
PRP increased migration and proliferation, but reduced the 
osteogenic differentiation of bone marrow-derived MSCs in 
vitro [14, 19]. However, in this study, aPPP did not suppress 
ALP activity at any concentration; therefore, these inhibi-
tory effects may be associated with substances that are de-
rived from platelets. 
Substantial variations in the PRP and WB platelet counts 
were noted. The PRP platelet count was correlated with both 
donor WB platelet counts and recovery rates. The GF con-
centrations also showed considerable between-donor varia-
tions. The aPRP GF concentrations, except for IGF-1, were 
significantly higher than the aPPP GF concentrations. This 
suggested that TGF-β1, PDGFs, FGF-b, and VEGF were de-
Table 4. Selected variables according to the stepwise multiple regression re-
sults
Variables
Unstandardized 
coefficients
Standardized 
coefficients Significance
B Standard Error Beta
The amount of DNA
  (constant) 3,025.6 371.8 0.000
  TGF-β1 11.9 3.1 0.500 0.000
  Age -10.2 4.1 -0.324 0.017
ALP/DNA 
  (constant) 0.010 0.001 0.000
  PDGF-BB <0.001 <0.001 -0.418 0.008
R=0.674, R
2=0.454 for the amount of DNA.
R=0.418, R
2=0.175 for ALP/DNA.
Abbreviations: TGF-β1, transforming growth factor-β1; PDGF, platelet-derived growth 
factor.Cho HS, et al.  •  Individual Variation of the PRP Effect
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rived from platelets, but that IGF-1 did not originate from 
platelets [20]. The concentrations of TGF-β1, PDGFs, and 
FGF-b were correlated with the WB and PRP platelet counts, 
more strongly with the PRP than WB platelet counts. Weib-
rich et al. [9] noted that the GFs contents were not well cor-
related with either the WB or PRP platelet counts; however, 
this result may be attributed to the use of non-activated PRP 
in their study. In our study, PDGF-BB and IGF-1 concentra-
tion were negatively correlated with age, indicating that GFs 
vary between individuals according to the differences in 
platelet count and donor age. 
Since the efficacy of PRP is based on the production and 
release of multiple GFs when platelets are activated, we hy-
pothesized that differing GF concentrations might result in 
different effects on MSC proliferation or osteogenic differ-
entiation. To verify this hypothesis, HMSCs from 39 donors 
were cultured with 10% aPRP, and the relationships between 
GF concentrations and DNA contents or ALP activity were 
evaluated. The individual variations in PRP GF release pat-
terns were noted, and could be divided into 5 groups based 
on cluster analysis. 
The levels of TGF-β1, PDGFs, and IGF-1 differed between 
the groups. VEGF and FGF-b displayed tendencies similar 
to those of TGF-β1 and PDGFs, but these differences were 
not significant. IGF-1 showed a different tendency, suggest-
ing that IGF-1 originated from a different source than the 
other GFs. The DNA content of HMSCs is significantly 
higher in groups with higher TGF-β1 and PDGF contents. 
These results indicated that individual characteristic release 
patterns of aPRP GFs may be attributable to GFs derived 
from platelets and IGF-1 and may influence the different 
proliferative effects. 
We then performed multiple regression analysis to evalu-
ate independent factors that could affect DNA content or 
ALP activity. Multiple regression analysis results showed 
that the quantity of DNA was positively correlated with the 
concentration of TGF-β1 and was negatively correlated 
with donor age. This finding indicates that TGF-β1 is the 
most mitogenic of the aPRP GFs. TGF-β1 has been shown 
to stimulate the proliferation of undifferentiated MSCs, and 
its effects vary with the amount applied [21]. Previous re-
ports have suggested that PDGF-BB and FGF could stimu-
late the proliferation of MSCs or osteoblastic cells at a con-
centration of 5 ng/mL [22, 23] and that the concentrations 
of these GFs in 10% aPRP were substantially lower than 5 
ng/mL. The lack of a detectable effect of PDGF-BB and FGF 
on MSC proliferation in this study might have been the re-
sult of low concentrations of PDGF-BB and FGF that might 
be present in 10% aPRP. 
Although the cellular ALP activity did not differ among 
groups derived from cluster analysis, aPRP inhibited the 
ALP activity separately from aPPP. Thus, an unknown sub-
stance released from the platelets has been hypothesized to 
suppress osteogenic differentiation. Multiple regression 
analysis showed that the ALP activity was negatively corre-
lated with the concentration of PDGF-BB in our study. 
Tokunaga et al. [24] noted that the depletion of PDGFR-β in 
MSCs attenuated mitogenic and migratory responses, but 
enhanced osteogenic differentiation. Additionally, Ranly re-
ported that PDGF-BB inhibited demineralized bone matrix-
induced intramuscular cartilage and bone formation in a 
dose-dependent manner [7]. These findings, coupled with 
the results of our study, indicate that the suppression of ALP 
activity by aPRP is attributable to PDGF-BB. However, the 
inhibitory effects of PRP on osteogenesis remain somewhat 
unclear. The principal disadvantage of this study was that 
only ALP activity was used as an osteogenic marker, primar-
ily because of the limited available volume of PRP. Kanno et 
al. [25] demonstrated that ALP activity was suppressed dur-
ing cell growth, but was enhanced when the cells achieved 
confluence. Further studies for optimal duration and the ef-
fect on other osteogenic markers, such as osteopontin or 
RUNX2, should be conducted to demonstrate the osteo-
genic effects of PRP.
In conclusion, aPRPs stimulate MSC proliferation in a 
dose dependent manner, and they suppress ALP activity 
during cell proliferation. The GF concentrations reveal indi-
vidual variations that may result in different biologic effects 
of aPRP. MSC proliferation was positively correlated with 
TGF-β1 concentration, and ALP activity was negatively 
correlated with PDGF-BB concentration in aPRP. These re-
sults indicate that individual differences in GFs should be 
taken into consideration in order to ensure reliable inter-
pretation of the biologic function and standardized applica-
tion of PRP. 
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